Lara Costa

Prof. Lara Costa

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Biological Psychiatry
Verified
Journal Article
Closed access
Lara CostaLara Costa
Lara Costa
MSMichela Spatuzza
Michela Spatuzza
SDSimona D'ANtoni
Simona D'ANtoni
CBCarmela M. Bonaccorso
Carmela M. Bonaccorso
CTChiara Trovato
Chiara Trovato
LCLucia Ciranna
Lucia Ciranna

24 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
EAElisabetta Aloisi
Elisabetta Aloisi
KCKaty Le Corf
Katy Le Corf
JDJulien Dupuis
Julien Dupuis
PZPei Zhang
Pei Zhang
MGMelanie Ginger
Melanie Ginger
AFAndreas Frick
Andreas Frick
Metabotropic glutamate receptor subtype 5 (mGluR5) is crucially implicated in the pathophysiology of Fragile X Syndrome (FXS); however, its dysfunction at the sub-cellular level, and related synaptic and cognitive phenotypes are unexplored. Here, we probed the consequences of mGluR5/Homer scaffold disruption for mGluR5 cell-surface mobility, synaptic N-methyl-D-aspartate receptor (NMDAR) function, and behavioral phenotypes in the second-generationFmr1knockout (KO) mouse. Using single-molecule tracking, we found that mGluR5 was significantly more mobile at synapses in hippocampalFmr1KO neurons, causing an increased synaptic surface co-clustering of mGluR5 and NMDAR. This correlated with a reduced amplitude of synaptic NMDAR currents, a lack of their mGluR5-activated long-term depression, and NMDAR/hippocampus dependent cognitive deficits. These synaptic and behavioral phenomena were reversed by knocking down Homer1a inFmr1KO mice. Our study provides a mechanistic link between changes of mGluR5 dynamics and pathological phenotypes of FXS, unveiling novel targets for mGluR5-based therapeutics.

12 March 2015 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
PDF file
Lara CostaLara Costa
Lara Costa
LSLara M. Sardone
Lara M. Sardone
ELEnza Lacivita
Enza Lacivita
Marcello LeopoldoMarcello Leopoldo
Marcello Leopoldo
LCLucia Ciranna
Lucia Ciranna
Serotonin 5-HT7 receptors are expressed in the hippocampus and modulate the excitability of hippocampal neurons. We have previously shown that 5-HT7 receptors modulate glutamate-mediated hippocampal synaptic transmission and long-term synaptic plasticity. In particular, we have shown that activation of 5-HT7 receptors reversed metabotropic glutamate receptor-mediated long-term depression (mGluR-LTD) in wild-type (wt) and in Fmr1 KO mice, a mouse model of Fragile X syndrome in which mGluR-LTD is abnormally enhanced, suggesting that 5-HT7 receptor agonists might be envisaged as a novel therapeutic strategy for Fragile X syndrome. In this perspective, we have characterized the basic in vitro pharmacokinetic properties of novel molecules with high binding affinity and selectivity for 5-HT7 receptors and we have tested their effects on synaptic plasticity using patch clamp on acute hippocampal slices. Here we show that LP-211, a high affinity selective agonist of 5-HT7 receptors, reverses mGluR-LTD in wt and Fmr1 KO mice, correcting a synaptic malfunction in the mouse model of Fragile X syndrome. Among novel putative agonists of 5-HT7 receptors, the compound BA-10 displayed improved affinity and selectivity for 5-HT7 receptors and improved in vitro pharmacokinetic properties with respect to LP-211. BA-10 significantly reversed mGluR-LTD in the CA3-CA1 synapse in wt and Fmr1KO mice, indicating that BA-10 behaved as a highly effective agonist of 5-HT7 receptors and reduced exaggerated mGluR-LTD in a mouse model of Fragile X Syndrome. On the other side, the compounds RA-7 and PM-20, respectively arising from in vivo metabolism of LP-211 and BA-10, had no effect on mGluR-LTD thus did not behave as agonists of 5-HT7 receptors in our conditions. The present results provide information about the structure-activity relationship of novel 5-HT7 receptor agonists and indicate that LP-211 and BA-10 might be used as novel pharmacological tools for the therapy of Fragile X syndrome.

27 April 2011 in Hippocampus
Verified
Journal Article
Closed access
PDF file
Lara CostaLara Costa
Lara Costa
CTC. Trovato
C. Trovato
SMS.A. Musumeci
S.A. Musumeci
MCMaria Vincenza Catania
Maria Vincenza Catania
LCLucia Ciranna
Lucia Ciranna

1 September 2008 in Neuropharmacology
Verified
Journal Article
Closed access
MCMarzia Castiglione
Marzia Castiglione
MCMarco Calafiore
Marco Calafiore
Lara CostaLara Costa
Lara Costa
MSMaria Angela Sortino
Maria Angela Sortino
Ferdinando NicolettiFerdinando Nicoletti
Ferdinando Nicoletti
ACAgata Copani
Agata Copani

23 August 2018 in Cerebral Cortex
Verified
Journal Article
Closed access
PDF file
TMThomas Maurin
Thomas Maurin
FMFrancesca Melancia
Francesca Melancia
MJMarielle Jarjat
Marielle Jarjat
LCLiliana Castro
Liliana Castro
Lara CostaLara Costa
Lara Costa
Barbara BardoniBarbara Bardoni
Barbara Bardoni
The fragile X mental retardation protein (FMRP) is an RNA-binding protein involved in translational regulation of mRNAs that play key roles in synaptic morphology and plasticity. The functional absence of FMRP causes the fragile X syndrome (FXS), the most common form of inherited intellectual disability and the most common monogenic cause of autism. No effective treatment is available for FXS. We recently identified the Phosphodiesterase 2A (Pde2a) mRNA as a prominent target of FMRP. PDE2A enzymatic activity is increased in the brain of Fmr1-KO mice, a recognized model of FXS, leading to decreased levels of cAMP and cGMP. Here, we pharmacologically inhibited PDE2A in Fmr1-KO mice and observed a rescue both of the maturity of dendritic spines and of the exaggerated hippocampal mGluR-dependent long-term depression. Remarkably, PDE2A blockade rescued the social and communicative deficits of both mouse and rat Fmr1-KO animals. Importantly, chronic inhibition of PDE2A in newborn Fmr1-KO mice followed by a washout interval, resulted in the rescue of the altered social behavior observed in adolescent mice. Altogether, these results reveal the key role of PDE2A in the physiopathology of FXS and suggest that its pharmacological inhibition represents a novel therapeutic approach for FXS.